We are preparing to initiate pivotal programs for multiple additional assets by the end of this year, including marizomib in first line glioblastoma, BB2121 in relapsed refractory myeloma, JCAR017 in relapsed refractory large B-cell lymphoma, CC-122 in relapsed refractory lymphoma, IDHIFA in first line AML and durvalumab in myeloma, MDS and AML